Alto Neuroscience, Inc. $ANRO is Spruce Street Capital LP’s 6th Largest Position

Spruce Street Capital LP raised its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 494.7% during the first quarter, Holdings Channel.com reports. The fund owned 1,325,210 shares of the company’s stock after buying an additional 1,102,366 shares during the period. Alto Neuroscience accounts for approximately 7.0% of Spruce Street Capital LP’s portfolio, making the stock its 6th largest position. Spruce Street Capital LP’s holdings in Alto Neuroscience were worth $29,116,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Torren Management LLC bought a new position in shares of Alto Neuroscience in the fourth quarter worth about $62,000. XTX Topco Ltd raised its stake in Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares during the period. Renaissance Technologies LLC lifted its holdings in Alto Neuroscience by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after purchasing an additional 6,100 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after purchasing an additional 8,148 shares in the last quarter. Finally, AlphaCore Capital LLC boosted its stake in Alto Neuroscience by 100.0% in the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $356,000 after purchasing an additional 10,000 shares during the period.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $26.72 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. Alto Neuroscience, Inc. has a 1-year low of $3.00 and a 1-year high of $28.85. The business has a 50 day simple moving average of $23.47 and a two-hundred day simple moving average of $21.50. The stock has a market capitalization of $937.53 million, a PE ratio of -11.04 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, research analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several recent analyst reports. Zacks Research cut shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday. JonesTrading dropped their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Bank of America assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Wolfe Research initiated coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.